Vikas Sinha - 02 Jul 2024 Form 4 Insider Report for Allovir, Inc. (KLRS)

Role
Officer Title: President and Chief Financial Officer, Director, 10%+ Owner
Signature
/s/ Brett Hagen, as Attorney-in-Fact
Issuer symbol
KLRS
Transactions as of
02 Jul 2024
Net transactions value
-$676
Form type
4
Filing time
03 Jul 2024, 16:14:43 UTC
Previous filing
21 May 2024
Next filing
23 Jul 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALVR Common Stock Sale $676 -939 -0.08% $0.7200 1,165,394 02 Jul 2024 Direct F1, F2
holding ALVR Common Stock 16,674,766 02 Jul 2024 Shares held by ElevateBio LLC F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
F2 Includes 36,337 shares acquired under the Allovir, Inc. 2020 Employee Stock Purchase Plan on June 28, 2024.
F3 Shares held by ElevateBio. The Reporting Person is a director and Chief Financial Officer of ElevateBio, and may be deemed to have shared voting and investment power of the shares held by ElevateBio. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

Officer Title: President and Chief Financial Officer